Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.41 |
| ▸ | LCAT | P04180 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552058 | 0.81 | KMT2A (0.61) | HSD11B1KMT2ATRPV1MALT1ALDH1A1 | |
| SCHEMBL17206944 | 0.81 | HSD11B1 (0.50) | HSD11B1KMT2ATRPV1MALT1LCAT | |
| SCHEMBL3436628 | 0.80 | HSD11B1 (0.49) | HSD11B1KMT2ATRPV1MALT1KDM4E | |
| SCHEMBL3436511 | 0.80 | SMO (0.53) | HSD11B1KMT2ATRPV1MALT1KDM4E | |
| SCHEMBL2804196 | 0.80 | HSD11B1 (0.49) | HSD11B1KMT2ATRPV1MALT1KDM4E | |
| SCHEMBL238160 | 0.78 | KDM4E (0.60) | HSD11B1KMT2ATRPV1MALT1KDM4E | |
| SCHEMBL18951797 | 0.77 | CYP1A2 (0.68) | HSD11B1ALDH1A1 | |
| SCHEMBL2560551 | 0.77 | KMT2A (0.54) | KMT2ATRPV1MALT1KDM4ERECQL | |
| SCHEMBL7134019 | 0.77 | OPRK1 (0.58) | KMT2AKDM4E | |
| SCHEMBL24126285 | 0.77 | HSD11B1 (0.47) | HSD11B1KMT2ATRPV1MALT1LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HSD11B1 3972/4885KMT2A 1707/4885TRPV1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.